Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	326	104-31-4

Description:

Molecule	Description
Synonyms: tessalon benzonatate benzononantin benzononatine	Molecular weight: Formula: C12H17NO2(C2H4O)7-9 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

tessalon
benzonatate
benzononantin
benzononatine

Molecular weight:
Formula: C12H17NO2(C2H4O)7-9
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	14.20 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Feb. 10, 1958	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia	179.21	13.33	463	23162	637596	89967226
Bronchitis	148.60	13.33	191	23434	152736	90452086
Cough	144.11	13.33	305	23320	368657	90236165
Completed suicide	126.75	13.33	172	23453	144886	90459936
COVID-19	119.35	13.33	181	23444	168662	90436160
Product dose omission issue	110.17	13.33	238	23387	291449	90313373
Upper respiratory tract infection	85.63	13.33	134	23491	128184	90476638
Cardiac arrest	79.11	13.33	116	23509	104819	90500003
Asthma	78.44	13.33	186	23439	241974	90362848
Maternal exposure during pregnancy	77.41	13.33	4	23621	360059	90244763
Influenza	72.32	13.33	130	23495	139134	90465688
Synovitis	69.83	13.33	4	23621	329748	90275074
Dyspnoea	69.59	13.33	429	23196	880526	89724296
Contraindicated product administered	67.44	13.33	4	23621	320135	90284687
Glossodynia	62.18	13.33	6	23619	321773	90283049
Systemic lupus erythematosus	62.05	13.33	10	23615	361886	90242936
Death	61.83	13.33	259	23366	456292	90148530
Impaired quality of life	61.81	13.33	50	23575	23094	90581728
Electrocardiogram change	58.16	13.33	17	23608	777	90604045
Illness	56.61	13.33	87	23538	81882	90522940
Pericarditis	55.04	13.33	4	23621	270147	90334675
Treatment failure	52.99	13.33	8	23617	303920	90300902
Wound	52.77	13.33	8	23617	302972	90301850
Therapy interrupted	52.42	13.33	65	23560	50043	90554779
Chronic obstructive pulmonary disease	51.88	13.33	79	23546	73750	90531072
Infusion related reaction	47.06	13.33	25	23600	416755	90188067
Respiratory arrest	46.25	13.33	50	23575	33261	90571561
Conduction disorder	45.11	13.33	17	23608	1718	90603104
Hypoxia	44.68	13.33	73	23552	72326	90532496
Hepatic enzyme increased	43.19	13.33	20	23605	360716	90244106
Arthropathy	41.30	13.33	22	23603	366220	90238602
Angiokeratoma	40.80	13.33	9	23616	128	90604694
Joint swelling	40.40	13.33	43	23582	503257	90101565
Drug intolerance	39.68	13.33	35	23590	447556	90157266
Dermatitis atopic	39.38	13.33	39	23586	23433	90581389
Acute respiratory failure	39.12	13.33	52	23573	42866	90561956
Drug ineffective	36.57	13.33	212	23413	1384086	89220736
General physical health deterioration	36.27	13.33	24	23601	355091	90249731
Blister	35.75	13.33	11	23614	254987	90349835
Exposure during pregnancy	33.94	13.33	10	23615	238400	90366422
Therapeutic product effect decreased	33.82	13.33	15	23610	277556	90327266
C-reactive protein increased	33.45	13.33	4	23621	181385	90423437
Hospitalisation	32.69	13.33	90	23535	128010	90476812
Lower respiratory tract infection	31.41	13.33	13	23612	250646	90354176
Toxicity to various agents	31.17	13.33	153	23472	287693	90317129
Seasonal allergy	31.03	13.33	34	23591	22949	90581873
Irritable bowel syndrome	30.84	13.33	8	23617	207440	90397382
Productive cough	30.29	13.33	64	23561	76999	90527823
Impaired healing	29.58	13.33	12	23613	234187	90370635
Inflammation	28.30	13.33	6	23619	178586	90426236
COVID-19 pneumonia	26.49	13.33	28	23597	18149	90586673
White blood cell count decreased	25.08	13.33	98	23527	167011	90437811
Rheumatoid arthritis	24.83	13.33	35	23590	362579	90242243
Liver injury	24.55	13.33	7	23618	170560	90434262
Drug interaction	24.02	13.33	22	23603	276431	90328391
Surgery	23.40	13.33	42	23583	44845	90559977
Pulmonary embolism	23.22	13.33	81	23544	130739	90474083
Viral infection	23.20	13.33	40	23585	41374	90563448
Mobility decreased	22.93	13.33	19	23606	250715	90354107
Back pain	22.73	13.33	151	23474	317024	90287798
Swelling	22.68	13.33	47	23578	419011	90185811
Joint range of motion decreased	22.66	13.33	4	23621	135639	90469183
Respiratory failure	22.49	13.33	75	23550	118343	90486479
Cardio-respiratory arrest	20.94	13.33	49	23576	63091	90541731
Musculoskeletal stiffness	20.92	13.33	28	23597	296504	90308318
Seizure	20.90	13.33	87	23538	152542	90452280
Respiratory tract infection	20.86	13.33	47	23578	59031	90545791
Pulse absent	20.36	13.33	15	23610	6040	90598782
Decerebrate posture	19.86	13.33	5	23620	129	90604693
Urinary tract infection	19.82	13.33	142	23483	305490	90299332
Off label use	19.80	13.33	188	23437	1102064	89502758
Haemoptysis	19.75	13.33	33	23592	33287	90571535
Bursitis	19.71	13.33	5	23620	131649	90473173
Fatigue	18.98	13.33	413	23212	1153610	89451212
Sinus disorder	18.94	13.33	33	23592	34414	90570408
Product dose omission in error	18.92	13.33	25	23600	20478	90584344
Alopecia	18.88	13.33	66	23559	495005	90109817
Nasal congestion	18.75	13.33	56	23569	83358	90521464
Ill-defined disorder	18.19	13.33	13	23612	184878	90419944
Type 2 diabetes mellitus	17.85	13.33	16	23609	203228	90401594
Conjunctival pigmentation	17.52	13.33	4	23621	67	90604755
Fibromyalgia	17.22	13.33	17	23608	206252	90398570
Intentional product misuse	16.35	13.33	56	23569	89548	90515274
Facet joint syndrome	16.22	13.33	3	23622	98386	90506436
Product use issue	16.21	13.33	39	23586	329880	90274942
Wound infection	16.00	13.33	4	23621	106398	90498424
Full blood count decreased	15.75	13.33	28	23597	29661	90575161
Nausea	15.65	13.33	389	23236	1109927	89494895
Deep vein thrombosis	15.63	13.33	56	23569	91564	90513258
Pneumothorax	15.61	13.33	22	23603	19145	90585677
Chills	15.61	13.33	72	23553	131909	90472913
Abdominal discomfort	15.41	13.33	68	23557	477260	90127562
Diarrhoea	15.37	13.33	336	23289	938854	89665968
Hypervolaemia	15.01	13.33	29	23596	32728	90572094
Palmar erythema	14.71	13.33	8	23617	1903	90602919
Fall	14.33	13.33	190	23435	481620	90123202
Hospice care	14.23	13.33	15	23610	9689	90595133
Sleep disorder due to a general medical condition	14.05	13.33	34	23591	44704	90560118
Therapy cessation	14.05	13.33	30	23595	36331	90568491
Therapeutic product effect incomplete	13.98	13.33	18	23607	193878	90410944
Hypersensitivity	13.94	13.33	66	23559	454611	90150211
Osteoporosis	13.82	13.33	4	23621	96527	90508295
Coma	13.78	13.33	46	23579	72586	90532236
Psoriatic arthropathy	13.75	13.33	24	23601	228311	90376511
Electrocardiogram abnormal	13.50	13.33	15	23610	10283	90594539

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia	135.32	16.07	308	10047	421841	42189139
Death	64.67	16.07	255	10100	470930	42140050
Cough	64.59	16.07	137	10218	177966	42433014
Conduction disorder	53.89	16.07	21	10334	2497	42608483
Bronchitis	45.97	16.07	57	10298	47144	42563836
Intentional product use issue	43.43	16.07	69	10286	71764	42539216
Acute respiratory failure	36.35	16.07	46	10309	38812	42572168
Dyspnoea	31.43	16.07	199	10156	442422	42168558
Product dose omission issue	30.96	16.07	95	10260	154270	42456710
Therapy interrupted	30.35	16.07	32	10323	22218	42588762
Electrocardiogram QT prolonged	30.27	16.07	47	10308	47898	42563082
Fatigue	29.77	16.07	194	10161	435447	42175533
Electrocardiogram QRS complex prolonged	26.69	16.07	17	10338	5806	42605174
Nasopharyngitis	23.06	16.07	58	10297	83938	42527042
Renal tubular injury	21.85	16.07	10	10345	1769	42609211
COVID-19	21.06	16.07	69	10286	115879	42495101
Bundle branch block	20.12	16.07	8	10347	1002	42609978
Hypoxia	20.01	16.07	49	10306	69737	42541243
Drug ineffective	18.91	16.07	84	10271	630113	41980867
Influenza	18.19	16.07	44	10311	62131	42548849
Atrioventricular block first degree	18.15	16.07	14	10341	6477	42604503
Liver function test increased	17.63	16.07	23	10332	19975	42591005
Bundle branch block right	17.43	16.07	15	10340	8091	42602889
Respiratory failure	17.12	16.07	69	10286	128063	42482917
Non-small cell lung cancer	16.76	16.07	12	10343	4962	42606018
Plasma cell myeloma	16.49	16.07	36	10319	47542	42563438
Atrial fibrillation	16.19	16.07	72	10283	139521	42471459
Sarcomatoid carcinoma of the lung	16.14	16.07	3	10352	18	42610962

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia	235.42	13.36	611	27174	876103	109685411
Bronchitis	133.02	13.36	180	27605	156852	110404662
Cough	126.65	13.36	325	27460	461316	110100198
Completed suicide	115.01	13.36	213	27572	242168	110319346
Death	110.02	13.36	405	27380	698464	109863050
Product dose omission issue	101.35	13.36	239	27546	321543	110239971
Conduction disorder	100.56	13.36	38	27747	4017	110557497
COVID-19	97.55	13.36	200	27585	244860	110316654
Acute respiratory failure	80.62	13.36	97	27688	75163	110486351
Dyspnoea	79.60	13.36	512	27273	1106360	109455154
Influenza	66.05	13.36	137	27648	168964	110392550
Cardiac arrest	65.01	13.36	149	27636	196604	110364910
Hypoxia	62.85	13.36	115	27670	129400	110432114
Upper respiratory tract infection	59.22	13.36	113	27672	131215	110430299
Synovitis	56.54	13.36	3	27782	274089	110287425
Impaired quality of life	50.27	13.36	49	27736	29968	110531546
Electrocardiogram change	49.39	13.36	17	27768	1374	110560140
Asthma	46.97	13.36	154	27631	250137	110311377
Chronic obstructive pulmonary disease	45.64	13.36	91	27694	109067	110452447
Intentional product use issue	45.15	13.36	151	27634	247755	110313759
Contraindicated product administered	44.82	13.36	5	27780	248262	110313252
Toxicity to various agents	43.83	13.36	237	27548	480318	110081196
C-reactive protein increased	43.09	13.36	3	27782	217916	110343598
Treatment failure	42.30	13.36	9	27776	277225	110284289
Pericarditis	40.61	13.36	4	27781	219110	110342404
Drug intolerance	39.31	13.36	27	27758	406485	110155029
Infusion related reaction	38.65	13.36	24	27761	381138	110180376
Drug ineffective	38.36	13.36	225	27560	1520315	109041199
Productive cough	38.21	13.36	87	27698	114218	110447296
Hypervolaemia	37.79	13.36	54	27731	49406	110512108
General physical health deterioration	37.60	13.36	31	27754	425264	110136250
Electrocardiogram QRS complex prolonged	37.56	13.36	29	27756	12992	110548522
Illness	37.39	13.36	71	27714	82100	110479414
Systemic lupus erythematosus	37.31	13.36	9	27776	254329	110307185
Angiokeratoma	37.01	13.36	9	27776	208	110561306
Respiratory arrest	36.50	13.36	58	27727	58241	110503273
Respiratory failure	35.57	13.36	127	27658	215205	110346309
Glossodynia	34.29	13.36	7	27778	221997	110339517
Therapy interrupted	33.18	13.36	51	27734	49771	110511743
Seizure	32.81	13.36	126	27659	221059	110340455
Intentional product misuse	30.72	13.36	88	27697	132816	110428698
Sinus tachycardia	30.27	13.36	46	27739	44447	110517067
Pneumonitis	29.85	13.36	62	27723	76469	110485045
Therapeutic product effect decreased	29.84	13.36	12	27773	244304	110317210
Fatigue	29.77	13.36	449	27336	1215509	109346005
Joint swelling	29.42	13.36	41	27744	442804	110118710
Arthropathy	29.28	13.36	18	27767	287504	110274010
Dermatitis atopic	29.12	13.36	34	27751	25507	110536007
COVID-19 pneumonia	29.04	13.36	41	27744	37102	110524412
Electrocardiogram QT prolonged	29.02	13.36	76	27709	108884	110452630
Nasal congestion	28.72	13.36	71	27714	98211	110463303
Inflammation	28.02	13.36	7	27778	193231	110368283
Lower respiratory tract infection	28.01	13.36	13	27772	243093	110318421
Exposure during pregnancy	26.44	13.36	5	27780	167419	110394095
Pulmonary embolism	26.13	13.36	115	27670	214359	110347155
Hospice care	25.99	13.36	23	27762	12450	110549064
Irritable bowel syndrome	25.73	13.36	5	27780	164210	110397304
Atrioventricular block first degree	25.29	13.36	24	27761	14201	110547313
Off label use	24.99	13.36	249	27536	1499936	109061578
Wound	24.82	13.36	14	27771	234423	110327091
Therapy cessation	24.54	13.36	42	27743	44815	110516699
Atrial fibrillation	22.77	13.36	116	27669	229526	110331988
Hospitalisation	22.63	13.36	83	27702	142410	110419104
Bursitis	22.50	13.36	3	27782	129915	110431599
Blister	22.10	13.36	15	27770	227361	110334153
Urinary tract infection	22.09	13.36	149	27636	326133	110235381
Liver injury	20.77	13.36	6	27779	150407	110411107
Back pain	20.29	13.36	161	27624	370835	110190679
Hepatic enzyme increased	20.04	13.36	31	27754	320861	110240653
Haemoptysis	19.23	13.36	50	27735	71304	110490210
Impaired healing	19.09	13.36	13	27772	196704	110364810
Bundle branch block	18.36	13.36	9	27776	1794	110559720
Pulse absent	18.10	13.36	18	27767	11274	110550240
Rheumatoid arthritis	17.71	13.36	30	27755	299583	110261931
Cardiac failure congestive	17.66	13.36	80	27705	150920	110410594
Swelling	17.42	13.36	39	27746	351002	110210512
Seasonal allergy	17.27	13.36	23	27762	19699	110541815
Decerebrate posture	17.09	13.36	5	27780	238	110561276
Conjunctival pigmentation	17.05	13.36	4	27781	79	110561435
Ear discomfort	16.33	13.36	17	27768	11232	110550282
Renal tubular injury	16.28	13.36	10	27775	3098	110558416
Rhabdomyolysis	16.26	13.36	5	27780	120396	110441118
Sarcomatoid carcinoma of the lung	16.04	13.36	3	27782	18	110561496
Pulmonary arterial hypertension	15.88	13.36	29	27756	32539	110528975
Liver disorder	15.78	13.36	8	27777	142235	110419279
Therapeutic product effect incomplete	15.58	13.36	20	27765	223785	110337729
Non-small cell lung cancer	15.28	13.36	14	27771	7921	110553593
Facet joint syndrome	15.06	13.36	3	27782	96825	110464689
Pleural effusion	15.06	13.36	86	27699	177623	110383891
Full blood count decreased	14.92	13.36	28	27757	32071	110529443
Joint range of motion decreased	14.84	13.36	6	27779	121826	110439688
Deep vein thrombosis	14.81	13.36	72	27713	139815	110421699
Musculoskeletal stiffness	14.78	13.36	30	27755	279792	110281722
Product administration interrupted	14.52	13.36	16	27769	11276	110550238
Myelosuppression	14.51	13.36	3	27782	94337	110467177
Suicide attempt	14.50	13.36	4	27781	103390	110458124
White blood cell count decreased	14.48	13.36	103	27682	229287	110332227
Fibromyalgia	14.42	13.36	13	27772	170896	110390618
Ill-defined disorder	14.39	13.36	11	27774	156842	110404672
Non-cardiac chest pain	14.07	13.36	15	27770	10183	110551331
Rhinovirus infection	13.95	13.36	16	27769	11773	110549741
Mobility decreased	13.82	13.36	24	27761	237398	110324116
Paranasal sinus discomfort	13.72	13.36	12	27773	6393	110555121
Insurance issue	13.58	13.36	15	27770	10597	110550917
Chills	13.47	13.36	88	27697	190492	110371022
Bundle branch block right	13.41	13.36	16	27769	12275	110549239

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R05DB01	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS Other cough suppressants
FDA PE	N0000009010	Decreased Tracheobronchial Stretch Receptor Activity
CHEBI has role	CHEBI:38867	anaesthetic
CHEBI has role	CHEBI:51177	antitussive
MeSH PA	D000996	Antitussive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
FDA EPC	N0000175796	Non-narcotic Antitussive

Related Drugs by ATC class:

R05DB Other cough suppressants 25 drugs

benproperine bibenzonium butamirate clobutinol clofedanol cloperastine dibunate dimethoxanate dropropizine droxypropine fedrilate gefapixant show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cough	indication	49727002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN					WOMBAT-PK

External reference:

ID	Source
D00242	KEGG_DRUG
18993	RXNORM
C0053229	UMLSCUI
CHEBI:3032	CHEBI
CHEMBL1374379	ChEMBL_ID
DB00868	DRUGBANK_ID
C029755	MESH_SUPPLEMENTAL_RECORD_UI
7611	IUPHAR_LIGAND_ID
651	INN_ID
5P4DHS6ENR	UNII
7699	PUBCHEM_CID
3024	MMSL
41691	MMSL
4260	MMSL
d00796	MMSL
32760-16-0	SECONDARY_CAS_RN
4018542	VANDF
001663	NDDF
31801005	SNOMEDCT_US
386030001	SNOMEDCT_US
5P4DHS6ENR	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1185	CAPSULE	100 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8403	CAPSULE	100 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6564	CAPSULE	100 mg	ORAL	ANDA	15 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7153	CAPSULE	100 mg	ORAL	ANDA	17 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-632	CAPSULE	200 mg	ORAL	ANDA	17 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-094	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-123	CAPSULE	200 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-129	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-027	CAPSULE	200 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-027	CAPSULE	200 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-028	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-028	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-029	CAPSULE	150 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	11788-029	CAPSULE	150 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	12634-826	CAPSULE, LIQUID FILLED	100 mg	ORAL	ANDA	12 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-031	CAPSULE	100 mg	ORAL	ANDA	11 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-191	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-760	CAPSULE	200 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-898	CAPSULE, LIQUID FILLED	100 mg	ORAL	ANDA	12 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-899	CAPSULE, LIQUID FILLED	200 mg	ORAL	ANDA	12 sections
Benzonatate 100 mg	Human Prescription Drug Label	1	25000-002	CAPSULE, LIQUID FILLED	100 mg	ORAL	ANDA	16 sections
Benzonatate 200 mg	Human Prescription Drug Label	1	25000-003	CAPSULE, LIQUID FILLED	200 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-956	CAPSULE	100 mg	ORAL	ANDA	11 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-957	CAPSULE	150 mg	ORAL	ANDA	11 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-958	CAPSULE	200 mg	ORAL	ANDA	11 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-147	CAPSULE	100 mg	ORAL	ANDA	16 sections
benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-634	CAPSULE	200 mg	ORAL	ANDA	16 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	42254-078	CAPSULE, LIQUID FILLED	100 mg	ORAL	ANDA	10 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-091	CAPSULE	100 mg	ORAL	ANDA	15 sections
Benzonatate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-092	CAPSULE	200 mg	ORAL	ANDA	15 sections

Ask DrugCentral

Try a sample question

benzonatate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: